A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
Clinical trial NCT04948554 · TERMINATED
Trial details
- NCT number
- NCT04948554
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-10
- Primary completion
- 2023-10-18
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.